The Genentech campus in South San Francisco is more than just a corporate address.
It is the starting point of a story that began with scribbles on napkins and, five decades later, continues to redraw the boundaries of what science can achieve.
Founded in 1976 from an unlikely meeting between scientist Herbert Boyer and investor Robert Swanson, Genentech established itself as the company that essentially invented modern biotechnology, paving the way for treatments that now save millions of lives.
But fifty years is long enough for the world to change dramatically, and the company knows that better than anyone.
Today, with Ashley Magargee at the helm and artificial intelligence fully entering the labs, Genentech is in the middle of one of the most ambitious transformations in its history. 🚀
This is not just about adopting new technologies because they are trendy.
What is at stake is rethinking everything from the physical layout of lab benches to the master plan for expanding the campus over the next 50 years, all fueled by a multibillion-dollar investment from Roche.
The question hanging in the air is: how does a company born from a three-hour conversation and some drawings on paper prepare for the next 50 years in a world dominated by data, algorithms, and discoveries happening at machine speed?
Receive the best innovation content in your email.
All the news, tips, trends, and resources you're looking for, delivered to your inbox.
By subscribing to the newsletter, you agree to receive communications from Método Viral. We are committed to always protecting and respecting your privacy.
That is exactly what we are going to explore here. 👇
A company that was born big before it even knew it would be
To understand the scale of what is happening right now at Genentech, it is worth taking a few steps back and remembering where it all came from. The very beginning is almost legendary. When venture capitalist Robert Swanson called recombinant DNA expert Herbert Boyer to propose starting a company, the scientist was not even convinced the meeting was worth his time. Boyer agreed to give him just ten minutes. The two met at a bar called Churchill’s, and three hours later, they had several drawings scribbled on napkins. That is where everything started.
The initial bet was a concept that most of the scientific community considered unlikely: using genetically modified bacteria to produce human proteins at scale. Boyer’s work to turn bacteria into actual insulin factories led to the approval of Humulin in 1982, a drug that was licensed to Eli Lilly. That moment was not just a milestone for the company — it was the beginning of an entire industry, biotechnology as we know it today. Since then, biotechnology has gone from being a distant idea to a mature sector, full of resources and buzzing with new concepts. New startups pop up practically every day, and the Genentech campus in South San Francisco is surrounded by smaller companies, many of them founded by former Genentech employees, such as Denali Therapeutics, Alumis, and Alector.
From that point on, Genentech built a portfolio of discoveries that truly set it apart. The major leap came with antibodies for cancer treatment, such as Rituxan, Herceptin, and Avastin, which started gaining approval in the late 1990s and early 2000s. Those products put the South San Francisco campus on the map as one of the most important addresses in global medicine.
Since Roche acquired full control of the company in 2009 in a 47-billion-dollar deal, Genentech has operated with a level of autonomy that is quite unusual for a subsidiary of a pharmaceutical group that size. That independence is not accidental — it is strategic. Roche understood that the culture of innovation that makes Genentech tick depends on an environment where scientists have the freedom to take risks, fail, and try again. This arrangement allowed the company to maintain its pace of research and development even after the acquisition, continuing to serve as one of Roche’s primary R&D engines. And Roche, of course, is one of the largest pharmaceutical companies in the world.
It is within this context of preserved independence and a legacy of innovation that Ashley Magargee stepped into the CEO role in 2024. Interestingly enough, she is not an outsider. Magargee started her career at the biotech more than two decades ago, in the market access side of oncology. When it comes to the company culture, she puts it pretty bluntly: be rigorous in science, be rigorous in innovation, but do not take yourself too seriously. The idea is to foster a truly collaborative and inclusive environment. In her view, even after the entire journey that included the Roche acquisition, Genentech’s core identity remains intact.
Artificial Intelligence inside the labs: what actually changes in practice
Saying a company is using artificial intelligence has become almost a cliché, but in Genentech’s case, what is happening goes well beyond an internal chatbot. The company is integrating AI models directly into its research and development workflows, which means algorithms are being used to predict how molecules will behave before any physical experiment even takes place. This has a massive impact on both the time and cost of developing new drugs. Historically, taking a drug from discovery to regulatory approval can take over a decade. As Magargee herself puts it, the point is not to do AI for the sake of AI. It is about discovering and developing the best possible medicine without spending ten years discovering the wrong one. 🧬
A big part of this shift is tied to the arrival of Aviv Regev, a computational biologist who joined Genentech in 2020 to lead the early research and development unit known as gRED. Regev has been championing a research structure built around a concept she calls the AI-powered lab-in-the-loop. This transition has also come with changes in scientific leadership, including the departure of experienced figures like vice presidents Vishva Dixit, Man-Wah Tan, and Todd McDevitt, as part of a gRED restructuring. When asked about those talent losses, Magargee was emphatic in saying that the core of Genentech’s identity is not changing. What is changing are the tools scientists get to use. According to her, the technology complements the enormous scientific capability of the organization without replacing or altering it.
Genentech’s AI and lab automation initiatives include partnerships with tech giants such as chipmaker Nvidia and Anthropic. The collaboration with Anthropic, for example, involved testing how the company’s AI agents could operate Genentech’s BCA protein assay. And a curious discovery came out of that experience: the typical horizontal layout of lab benches, designed so a human can reach the equipment, may not be as essential when a machine is the one doing the work.
As Magargee explained, bench science has always been a left-to-right process, and benches have been horizontal for a hundred years precisely because the workflow follows that logic. Now, the company is studying how much of the physical lab space really needs to be horizontal and how much could be vertical. It sounds like a small detail, but in an environment where time and space are extremely expensive resources, rethinking this can lead to real gains. Genentech’s location, nestled on the bay between San Francisco and Silicon Valley, gives the company easy access to the tech giants at the forefront of this transformation. 💡
The campus of the future: space, design, and the next 50 years
If there is one thing that sets Genentech’s approach apart right now, it is that the transformation is not being thought of only at the digital level. The iconic South San Francisco campus is undergoing a deep overhaul, and Magargee is now overseeing a master plan that looks ahead to the next 50 years. The premise is pretty straightforward: the physical environment where people work matters just as much as the tools they use. 🏗️
One of the central pieces of the first phase of this plan is moving scientists from the lower part of the campus, near the water, to a new, more centrally located gRED hub. Construction is expected to take place between 2027 and 2033. The main idea behind the move is to improve connection and collaboration among researchers. The project is so broad and open-ended that there is not even a defined number of phases yet. Magargee makes a point of praising Roche’s long-term vision, which encourages the company to do everything in a highly sustainable way.
This campus redesign is part of a 50-billion-dollar investment that the Swiss pharmaceutical giant announced in the United States, around the same time other major pharma companies were also making new commitments in the country. Among Roche’s initiatives is the opening of a new Innovation Center in Boston, inside Harvard’s Enterprise Research Campus. According to Magargee, that location puts scientists at the heart of one of the most dynamic research communities in the world, combining deep expertise in disease biology with the power of AI and data science to accelerate discoveries.
The CEO acknowledges that part of the 50 billion is a repackaging of investments already underway, but she emphasizes that there was also a specific decision to make new investments in the United States. The reason, she says, is America’s leadership in scientific talent and manufacturing, along with the need to ensure robust production and supply for patients in the country.
The campus holds constant reminders of its history. There are bees tended by Genentech employees who call themselves gBees, buzzing among the flowers near a circular health and fitness center — a nod to an old donut shop that used to stand there before the expansion of the world’s first biotechnology company. And there is also a famous bronze statue recreating the scene of Boyer and Swanson sitting at a table during the meeting that started it all. Employees often place coins in the cups held by the founders, hoping for good luck.
The pipeline that excites the leadership
Oncology remains an anchor area for Genentech, alongside hematology, neuroscience, immunology, and ophthalmology. But Magargee is also determined to take the company into new territory, such as cardiovascular, renal, and metabolic diseases. In her view, what works best is staying dedicated and focused on a disease area, deeply understanding the biology behind it, and building molecules that act precisely against it — investing end to end, from early research all the way to the patient.
Among the assets that excite the CEO the most are two small molecules already under FDA review. One is giredestrant, an oral selective estrogen receptor degrader awaiting an agency decision by late November as an adjuvant treatment for early-stage HR-positive breast cancer. Despite a surprising failure in a first-line study in metastatic breast cancer, Roche and Genentech still see enormous potential in the product. Fun fact: the name giredestrant actually comes from the company’s gRED unit.
The other molecule that excites Magargee is fenebrutinib, a BTK inhibitor being advanced for approval in multiple sclerosis, even though it has faced some safety-related concerns. Beyond those two, she points to trontinemab, an antibody engineered to cross the blood-brain barrier and treat Alzheimer’s disease. As she acknowledges, neuroscience and Alzheimer’s are really tough areas, and this molecule appears to have real potential to change clinical outcomes for patients who desperately need alternatives.
The combination of artificial intelligence with a physical expansion plan designed to span decades puts Genentech in a unique position: it is a company that looks toward the future without ignoring the weight and value of what it has already built.
Magargee presented these pipeline perspectives beneath a banner featuring Lamar, a lymphoma patient who was successfully treated with the bispecific antibody Columvi, approved in 2023. Lamar was seriously ill before entering a clinical trial, and his photo serves as a constant reminder for the company’s scientists not to get complacent. The message he leaves behind, according to Magargee, is clear: there must be a sense of urgency, because there are people whose lives depend on these clinical studies. Science needs to be pushed faster and faster.
What is happening in South San Francisco is not a break from the past. It is a smart continuation, where every new tool, every new square foot of the campus, and every artificial intelligence model integrated into the research and development pipeline serves the same purpose that motivated Boyer and Swanson during that three-hour conversation in 1976: finding better ways to treat diseases and improve people’s lives. Biotechnology has changed a lot since then, and Genentech has changed with it, but the north star remains the same. And that, at the end of the day, is what makes this story so fascinating to follow. 🔬
